In a recent literature review, the proportion of a favorable outcome in patients with neurosarcoidosis treated with TNF-alpha inhibitor was higher, compared to methotrexate, MMF and AZA (p < 0.00001) [8]. The gene discussed is TNF; the disease is neurosarcoidosis.